论文部分内容阅读
Dysregulation of Toll-like receptor 9(TLR9) signaling pathway can lead to various immunological diseases,such as systemic lupus erythematosus(SLE) and multiple sclerosis[1-2].Developing a potent and selective inhibitor with low toxicity is crucial to treat these diseases.